1. Alpha-Hederin induces incomplete autophagic injury in non-small cell lung cancer by interfering with the lysosomal acidification.
- Author
-
Jin F, Jiang X, Ni X, Yu S, Wu F, Shi X, Mao D, Wang H, Shi Q, Liu Y, and Xu Q
- Subjects
- Humans, Cell Line, Tumor, TOR Serine-Threonine Kinases metabolism, Autophagosomes metabolism, Autophagosomes drug effects, A549 Cells, Carcinoma, Non-Small-Cell Lung metabolism, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung drug therapy, Lysosomes metabolism, Lysosomes drug effects, Autophagy drug effects, Lung Neoplasms metabolism, Lung Neoplasms pathology, Lung Neoplasms drug therapy, Oleanolic Acid analogs & derivatives, Oleanolic Acid pharmacology, Saponins pharmacology
- Abstract
Lung cancer is the most common oncological disease worldwide, with non-small cell lung cancer accounting for approximately 85% of lung cancer cases. α-Hederin is a monodesmosidic triterpenoid saponin isolated from the leaves of Hedera helix L. or Nigella sativa and has been extensively studied for its antitumor activity against a variety of tumor cells. It has been suggested that α-Hederin is a potential regulator of autophagy and has high promise for application. However, the specific mechanism and characteristics of α-Hederin in regulating autophagy are not well understood. In this study, we confirmed the potential of α-Hederin application in lung cancer treatment and comprehensively explored the mechanism and characteristics of α-Hederin in regulating autophagy in lung cancer cells. Our results suggest that α-Hederin is an incomplete autophagy inducer that targets mTOR to activate the classical autophagic pathway, inhibits lysosomal acidification without significantly affecting the processes of autophagosome transport, lysosome biogenesis, autophagosome and lysosome fusion, and finally leads to impaired autophagic flux and triggers autophagic damage in NSCLC., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF